PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

• প্রধান লেখক: Kimiko Koiwai (লেখক), Raouf El‐Cheikh (লেখক), Hoai‐Thu Thai (লেখক), Claire Brillac (লেখক), Jean‐Baptiste Fau (লেখক), Christine Veyrat‐Follet (লেখক), Marie‐Laure Risse (লেখক), Helgi van deVelde (লেখক), Dorothée Semiond (লেখক), Laurent Nguyen (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Wiley, 2021-08-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Abstract This analysis describes the pharmacokinetic/pharmacodynamic (PK/PD) modeling framework that supported selection of the isatuximab (anti‐CD38 monoclonal antibody) dosing regimen alongside its early clinical development in patients with relapsed/refractory multiple myeloma (RRMM). The PK/PD m...